Skip to main content

Merck & Company(MRK-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low111.91
Day High116.53
Open:116.49
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)
Zacks Investment Research
Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
Zacks Investment Research
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
StockStory
3 Reasons We Love Merck (MRK)
MRK
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Savara (SVRA)
Motley Fool
Better Pharma Dividend Stock: Novartis vs. Merck
Tipranks
Morgan Stanley Sticks to Its Hold Rating for Merck & Company (MRK)
Zacks Investment Research
Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
Newswire.ca
New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada
Tipranks
Merck & Company (MRK) Gets a Buy from Wells Fargo
StockStory
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
MHK
StockStory
1 Momentum Stock on Our Buy List and 2 We Question
ALNT
Motley Fool
Which Dividend Pharma Stock Should a Value Investor Choose Today?
Tipranks
Merck & Company (MRK) Gets a Hold from Morgan Stanley
Zacks Investment Research
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
Tipranks
Merck & Company (MRK) Gets a Buy from Jefferies
Tipranks
Analysts’ Top Healthcare Picks: Oruka Therapeutics (ORKA), Merck & Company (MRK)
Motley Fool
Why Terns Pharmaceuticals Stock Rocked the Market in March
Zacks Investment Research
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Inventiva (IVA), Stereotaxis (STXS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Agios Pharma (AGIO)
Motley Fool
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500.
Zacks Investment Research
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Tipranks
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK) and Alto Neuroscience, Inc. (ANRO)
Tipranks
Erste Group Sticks to Its Hold Rating for Merck & Company (MRK)
Tipranks
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
Tipranks
Merck & Company (MRK) Gets a Buy from Jefferies
Tipranks
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)
Zacks Investment Research
Will AbbVie's Oncology Drugs Aid Top Line in 2026?
Will AbbVie's Oncology Drugs Aid Top Line in 2026?
Tipranks
Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK)
Tipranks
Cantor Fitzgerald Reaffirms Their Hold Rating on Merck & Company (MRK)
Tipranks
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and OmniAb (OABI)

Profile

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.